25 results
Primary objectives:1) To evaluate the safety of four different CHMI-trans protocols in healthy malaria-naïve volunteers challenged with Plasmodium falciparum by sporozoite challenge. 2) To determine the best CHMI-trans protocol for induction of…
The primary objective is to determine the safety and tolerability BCG vaccination followed by controlled human malaria infection; and to determine the protective efficacy BCG vaccination against a controlled human malaria infection.
Primary objectives:1) To evaluate the safety of CHMI-trans protocols in healthy malaria-naïve volunteers challenged with Plasmodium falciparum by sporozoite challenge and blood stage challenge. 2) To assess gametocyte infectiousness for Anopheles…
Primary Objective: To determine the safety and tolerability of NF135.C10 sporozoite immunization under chemoprophylaxisSecondary Objectives:• To determine the dose-dependent protective efficacy of NF135.C10 CPS-immunization against homologous…
Primary objective: To delineate the antibody repertoire directed against the pre-erythrocytic stages of Plasmodium falciparum induced by CPS-immunization.Secondary objectives: • To assess the functionality of CPS-immunization induced antibodies.• To…
Primary objective: To determine whether CPS-immunization with NF54 Plasmodium falciparum parasites provides protection against challenge with the genetically distinct P. falciparum clones, NF135.C10 or NF166.C8.Secondary objectives:• To investigate…
Primary Objective: To assess the proportion of volunteers who develop parasitemia after Controlled Human Malaria Infection with bites from one, two or five NF166.C8- or NF135.C10-infected mosquitoes.Secondary Objectives: To assess kinetics of…
Primary objective: To investigate whether CPS immunization confers protection to a blood stage challenge.Secondary objectives: • To study and compare parasitemia after challenge between study groups• To analyze and compare the immune responses…
Primary Objective: To determine if two thirds or one third of the CPS immunization dose still induces complete protection against an experimental malaria challenge. Secondary Objectives: • To study and compare parasitemia and kinetics of parasitemia…
• Primary objective: To achieve a 100% infection rate of human volunteers by intradermal injection of aseptic, purified, cryopreserved Pf sporozoites (PfSPZ Challenge). • Secondary objective: To compare parasite kinetics between different doses of…
• Primary objective (parasitological): To investigate the kinetics of parasitemia of different Plasmodium falciparum isolates• Secondary objective (immunological): To investigate parasite development and immunological properties of different…
Primary Objective: To compare protection against controlled Plasmodium falciparum malaria infection after immunization with sporozoites under chloroquine with immunization under mefloquine prophylaxis. Secondary Objectives: • To study and compare…
1. To determine clinical symptoms of Dientamoeba fragilis infection. 2. To evaluate the efficacy and safety of clioquinol versus metronidazol in the treatment of Dientamoeba fragilis in children.3. To evaluate the duration of positive PCR…
Primary objective (parasitological): To investigate the parasitaemic kinetics of three different Plasmodium falciparum isolates (NF54, NF135 and NF166) during a controlled human malaria infection.Secondary objective (parasitological, clinical and…
To determine protective immunity against a heterologous P. falciparum sporozoites re-challenge after previous CPS immunization and challenge.
This is a two part proof of efficacy study of KAF156 as a causal prophylactic agent in malaria. Results will be used to guide dose selection for further development of KAF156 in patients.
Objectives: • Primary objective (parasitological): To explore the longevity of immunity against P. falciparum sporozoite challenge that was induced in the EHMI-8 study. • Secondary objective (immunological): To dissect mechanisms of protection and…
To determine the usefulness of multiplex real-time pcr to detect asymptomatic parasitic infections in travellers returning from the tropics.
Phase 1 • Primary objective: to determine the safety and tolerability, including the attenuation phenotype of a novel late-arresting GAP, named GA2 parasite, administered by sequentially increasing numbers of mosquito bites.• Secondary objective: to…
Assessing the prevalence of pulmonary function testing abnormalities in HIV-infected patients with and without a history of PJP.